Skip to Main Content

Paper Details

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
Clin Cancer Res
10
2021
Author NameAffiliation
Niven MehraRadboud University Medical Center
Paul Hamberg
Emile E VoestOncode Institute
Emile E VoestNetherlands Cancer Institute
  • 1 - 4

Datasets

Release 1.2